Well-timed trades in Gilead Sciences Inc.’s options ahead of good news on the biopharmaceutical company’s COVID-19 drug treatment may draw regulatory scrutiny, experts said.
On April 17, Gilead’s shares jumped nearly 10 per cent after a media report detailing encouraging partial data from trials of the U.S. company’s experimental drug remdesivir in severe COVID-19 patients.
Those gains were dwarfed by a price jump in bullish options that traded in unusually high volume just hours before the report and that more than doubled in value overnight.
Remdesivir subsequently received the U.S. Food and Drug Administration’s emergency use authorization to treat COVID-19 patients on May 1.
Gilead has not heard from regulators regarding the trades, company spokesman Chris Ridley said, declining any additional comment on the matter.
Early in the trading day on April 16, with Gilead shares hovering around US$75, four large blocks of its options were purchased for about US$1.5-million each. Those unusually large trades bet that Gilead’s shares would rise north of US$80 to US$87.50 by mid-August.
“They are pretty big trades,” said Henry Schwartz, president of options analytics firm Trade Alert, adding that the fact they were made around the same time was also unusual. “It stands out,” he said.
In one of the trades, 3,143 calls betting Gilead’s shares would rise above US$85 by Aug. 21 were purchased for a total of US$1.6-million. Through April 17, the value of those contracts jumped to US$3.02-million, according to a Reuters analysis of trading data. The other three trades also made large gains.
On Friday, Gilead shares closed at US$77.83.
“This looks problematic,” said Howard Fischer, a partner with law firm Moses & Singer and former senior trial counsel at the U.S. Securities and Exchange Commission (SEC).
“When there is a specific spike in the firm’s trading activity – right before a finding is announced – it can become a red flag to regulators,” he said.
The SEC scans for unusual trades ahead of news announcements and has used such data to bring insider trading probes in the past, public filings show. The agency declined to comment.
While it is possible the trades were fortuitous, driven by bullish sentiment for drugmakers amid the pandemic, options trades in other pharmaceutical names did not show similar activity, according to a Reuters review.
“It does look like somebody had some sort of reason to pick that time of day to put a lot of capital to work on Gilead,” Mr. Schwartz said.
Be smart with your money. Get the latest investing insights delivered right to your inbox three times a week, with the Globe Investor newsletter. Sign up today.